Soleno Therapeutics (SLNO) Competitors $86.08 +3.45 (+4.18%) As of 03:41 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock SLNO vs. SNN, SOLV, PEN, STVN, GKOS, IRTC, NARI, TMDX, BLCO, and INSPShould you be buying Soleno Therapeutics stock or one of its competitors? The main competitors of Soleno Therapeutics include Smith & Nephew SNATS (SNN), Solventum (SOLV), Penumbra (PEN), Stevanato Group (STVN), Glaukos (GKOS), iRhythm Technologies (IRTC), Inari Medical (NARI), TransMedics Group (TMDX), Bausch + Lomb (BLCO), and Inspire Medical Systems (INSP). These companies are all part of the "medical equipment" industry. Soleno Therapeutics vs. Its Competitors Smith & Nephew SNATS Solventum Penumbra Stevanato Group Glaukos iRhythm Technologies Inari Medical TransMedics Group Bausch + Lomb Inspire Medical Systems Soleno Therapeutics (NASDAQ:SLNO) and Smith & Nephew SNATS (NYSE:SNN) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, media sentiment, earnings, institutional ownership, dividends, analyst recommendations, valuation and risk. Do institutionals & insiders have more ownership in SLNO or SNN? 97.4% of Soleno Therapeutics shares are owned by institutional investors. Comparatively, 25.6% of Smith & Nephew SNATS shares are owned by institutional investors. 6.4% of Soleno Therapeutics shares are owned by company insiders. Comparatively, 1.0% of Smith & Nephew SNATS shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Which has stronger earnings and valuation, SLNO or SNN? Smith & Nephew SNATS has higher revenue and earnings than Soleno Therapeutics. Soleno Therapeutics is trading at a lower price-to-earnings ratio than Smith & Nephew SNATS, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSoleno TherapeuticsN/AN/A-$175.85M-$4.62-18.63Smith & Nephew SNATS$5.81B2.27$412M$2.1613.95 Is SLNO or SNN more profitable? Smith & Nephew SNATS's return on equity of 0.00% beat Soleno Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Soleno TherapeuticsN/A -77.52% -63.44% Smith & Nephew SNATS N/A N/A N/A Do analysts recommend SLNO or SNN? Soleno Therapeutics presently has a consensus price target of $107.10, indicating a potential upside of 24.42%. Smith & Nephew SNATS has a consensus price target of $28.00, indicating a potential downside of 7.05%. Given Soleno Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Soleno Therapeutics is more favorable than Smith & Nephew SNATS.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Soleno Therapeutics 0 Sell rating(s) 0 Hold rating(s) 10 Buy rating(s) 1 Strong Buy rating(s) 3.09Smith & Nephew SNATS 0 Sell rating(s) 6 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Which has more risk & volatility, SLNO or SNN? Soleno Therapeutics has a beta of -2.63, suggesting that its share price is 363% less volatile than the S&P 500. Comparatively, Smith & Nephew SNATS has a beta of 0.69, suggesting that its share price is 31% less volatile than the S&P 500. Does the media refer more to SLNO or SNN? In the previous week, Soleno Therapeutics had 5 more articles in the media than Smith & Nephew SNATS. MarketBeat recorded 6 mentions for Soleno Therapeutics and 1 mentions for Smith & Nephew SNATS. Smith & Nephew SNATS's average media sentiment score of 1.22 beat Soleno Therapeutics' score of 0.77 indicating that Smith & Nephew SNATS is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Soleno Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Smith & Nephew SNATS 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummarySmith & Nephew SNATS beats Soleno Therapeutics on 8 of the 15 factors compared between the two stocks. Get Soleno Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SLNO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SLNO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SLNO vs. The Competition Export to ExcelMetricSoleno TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.34B$2.42B$5.50B$8.93BDividend YieldN/A1.79%5.38%4.12%P/E Ratio-18.668.9426.2519.86Price / SalesN/A665.31415.14113.78Price / CashN/A154.3736.4957.06Price / Book15.164.548.055.38Net Income-$175.85M$31.16M$3.16B$248.50M7 Day Performance0.34%0.15%1.78%2.78%1 Month Performance13.77%8.74%4.74%5.84%1 Year Performance116.66%2.17%35.81%20.06% Soleno Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SLNOSoleno Therapeutics4.6793 of 5 stars$86.08+4.2%$107.10+24.4%+95.4%$4.34BN/A-18.6630SNNSmith & Nephew SNATS3.604 of 5 stars$29.17+1.2%$28.00-4.0%+24.8%$12.77B$5.81B13.5017,349Positive NewsSOLVSolventum0.8839 of 5 stars$73.21-0.5%$80.29+9.7%+51.4%$12.67B$8.31B33.8922,000Positive NewsAnalyst UpgradePENPenumbra4.7309 of 5 stars$254.41-1.0%$302.40+18.9%+41.8%$9.85B$1.19B240.014,500Positive NewsSTVNStevanato GroupN/A€23.62+1.4%N/A+32.9%€7.15B€1.19B46.315,521Positive NewsAnalyst ForecastGap DownGKOSGlaukos4.4219 of 5 stars$96.80-3.3%$134.67+39.1%-12.6%$5.53B$383.48M-40.84780IRTCiRhythm Technologies1.2242 of 5 stars$150.95+3.6%$138.60-8.2%+37.1%$4.82B$591.84M-48.072,000Positive NewsNARIInari Medical0.4704 of 5 stars$79.97flat$69.22-13.4%N/A$4.68B$493.63M-59.24800TMDXTransMedics Group1.5784 of 5 stars$127.53+3.2%$127.33-0.2%-13.4%$4.31B$441.54M93.77210Positive NewsBLCOBausch + Lomb3.3387 of 5 stars$12.01+2.3%$15.54+29.5%-7.7%$4.25B$4.79B-11.6613,500INSPInspire Medical Systems4.8319 of 5 stars$129.88-0.8%$211.91+63.2%-5.8%$3.83B$840.11M59.851,246 Related Companies and Tools Related Companies Smith & Nephew SNATS Alternatives Solventum Alternatives Penumbra Alternatives Stevanato Group Alternatives Glaukos Alternatives iRhythm Technologies Alternatives Inari Medical Alternatives TransMedics Group Alternatives Bausch + Lomb Alternatives Inspire Medical Systems Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SLNO) was last updated on 7/2/2025 by MarketBeat.com Staff From Our PartnersGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredBank of America Says Gold Could Hit $4,000. Here How to Get PaidBank of America believes gold could hit $4,000 an ounce in the next 12 months. That's an 18% jump from toda...Investors Alley | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredIsrael-Iran WAR Could Destroy Trump's PresidencyThe missiles are already flying. Israel and Iran are now in direct military conflict — and this couldn't ha...American Alternative | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Soleno Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Soleno Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free SLNO Stock Alerts